欧盟最顶尖的药物机构支持Bio(Heven Bio)的ANKTIVA+BCG膀胱癌计划, The EU's top drug agency backed ImmunityBio’s ANKTIVA+BCG for bladder cancer, a key step toward approval.

ImmunityBio已获得欧洲药品管理局的积极推荐，将ANKTIVA与BCG结合用于治疗非肌肉侵入性膀胱癌及原位癌，标志着欧盟潜在批准的重要一步。 ImmunityBio has received a positive recommendation from the European Medicines Agency for ANKTIVA combined with BCG as a treatment for non-muscle invasive bladder cancer with carcinoma in situ, marking a significant step toward potential approval in the European Union.